Experts query case for GlaxoSmithKline's new 3-in-1 lung drug
April 18, 2018 at 17:00 PM EDT
LONDON, April 18 (Reuters) - Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.